{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T15:30:35Z","timestamp":1788363035234,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,3,13]]},"DOI":"10.7759\/cureus.36078","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T15:35:36Z","timestamp":1678721736000},"source":"Crossref","is-referenced-by-count":2,"title":["An In Vitro Susceptibility Study of Cefotaxime-Sulbactam on Clinical Bacterial Isolates From Various Regions in India: A Comparison With Ceftriaxone-Sulbactam"],"prefix":"10.7759","author":[{"given":"Ajitkumar A","family":"Gondane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dattatray B","family":"Pawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198325030-00001","article-title":"Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"25","author":"Carmine AA","year":"1983","unstructured":"Carmine AA, Brogden RN, Heel RC, Speight TM, Avery GS. Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1983, 25:223-89. 10.2165\/00003495-198325030-00001","journal-title":"Drugs"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198427060-00001","article-title":"Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use","volume":"27","author":"Richards DM","year":"1984","unstructured":"Richards DM, Heel RC, Brogden RN, Speight TM, Avery GS. Ceftriaxone. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1984, 27:469-527. 10.2165\/00003495-198427060-00001","journal-title":"Drugs"},{"key":"ref3","article-title":"Cefotaxime: microbiology, pharmacology, and clinical use","volume":"1","author":"Dudley MN","year":"1982","unstructured":"Dudley MN, Barriere SL. Cefotaxime: microbiology, pharmacology, and clinical use. Clin Pharm. 1982, 1:114-24.","journal-title":"Clin Pharm"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1155\/1995\/617610","article-title":"Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin","volume":"6","author":"Nath SK","year":"1995","unstructured":"Nath SK, Foster GA, Mandell LA, Rotstein C. Antimicrobial activity of ceftriaxone compared with cefotaxime in the presence of serum albumin. Can J Infect Dis. 1995, 6:21-7. 10.1155\/1995\/617610","journal-title":"Can J Infect Dis"},{"key":"ref5","unstructured":"National Treatment Guidelines for Antimicrobial Use in Infectious Diseases. Version 1.0 (2016). (2016). Accessed. 24\/12\/2022: https:\/\/ncdc.mohfw.gov.in\/showfile.php?lid=649."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/5070742","article-title":"Antimicrobial resistance profile of different clinical isolates against third-generation cephalosporins","volume":"2018","author":"Gashe F","year":"2018","unstructured":"Gashe F, Mulisa E, Mekonnen M, Zeleke G. Antimicrobial resistance profile of different clinical isolates against third-generation cephalosporins. J Pharm (Cairo). 2018, 2018:5070742. 10.1155\/2018\/5070742","journal-title":"J Pharm (Cairo)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh282","article-title":"Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae","volume":"54","author":"Muller A","year":"2004","unstructured":"Muller A, Lopez-Lozano JM, Bertrand X, Talon D. Relationship between ceftriaxone use and resistance to third-generation cephalosporins among clinical strains of Enterobacter cloacae. J Antimicrob Chemother. 2004, 54:173-7. 10.1093\/jac\/dkh282","journal-title":"J Antimicrob Chemother"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2000.6.319","article-title":"Antimicrobial drug resistance in non-typhoidal salmonellas from humans in England and Wales in 1999: decrease in multiple resistance in Salmonella enterica serotypes Typhimurium, Virchow, and Hadar","volume":"6","author":"Threlfall EJ","year":"2000","unstructured":"Threlfall EJ, Ward LR, Skinner JA, Graham A. Antimicrobial drug resistance in non-typhoidal salmonellas from humans in England and Wales in 1999: decrease in multiple resistance in Salmonella enterica serotypes Typhimurium, Virchow, and Hadar. Microb Drug Resist. 2000, 6:319-25. 10.1089\/mdr.2000.6.319","journal-title":"Microb Drug Resist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.625","article-title":"Neonatal septicemia isolates and resistance patterns in a tertiary care hospital of North India","volume":"4","author":"Kaistha N","year":"2009","unstructured":"Kaistha N, Mehta M, Singla N, Garg R, Chander J. Neonatal septicemia isolates and resistance patterns in a tertiary care hospital of North India. J Infect Dev Ctries. 2009, 4:55-7. 10.3855\/jidc.625","journal-title":"J Infect Dev Ctries"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1021\/jo400236f","article-title":"Overcoming resistance to \u03b2-lactam antibiotics","volume":"78","author":"Worthington RJ","year":"2013","unstructured":"Worthington RJ, Melander C. Overcoming resistance to \u03b2-lactam antibiotics. J Org Chem. 2013, 78:4207-13. 10.1021\/jo400236f","journal-title":"J Org Chem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC beta-lactamases","volume":"22","author":"Jacoby GA","year":"2009","unstructured":"Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009, 22:161-82. 10.1128\/CMR.00036-08","journal-title":"Clin Microbiol Rev"},{"key":"ref12","article-title":"Cefotaxime\/sulbactam: an important addition to the arsenal of inhibitor-protected beta-lactam antibiotics","volume":"64","author":"Yakovlev SV","year":"2019","unstructured":"Yakovlev SV, Suvorova MP. Cefotaxime\/sulbactam: an important addition to the arsenal of inhibitor-protected beta-lactam antibiotics. Antibiot Chemotherapy. 2019, 64:71-0.","journal-title":"Antibiot Chemotherapy"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.22159\/ijcpr.2018v10i3.27225","article-title":"A study on drug utilization pattern of cephalosporins in general medicine and surgical inpatient department","volume":"10","author":"Naveen V","year":"2018","unstructured":"Naveen V, Siddiq A, Chandana G. A study on drug utilization pattern of cephalosporins in general medicine and surgical inpatient department. Int J Curr Pharm Res. 2018, 10:33-6. 10.22159\/ijcpr.2018v10i3.27225","journal-title":"Int J Curr Pharm Res"},{"key":"ref14","article-title":"District Laboratory Practice in Tropical Countries Part 2, Second edition","author":"Cheesbrough M","year":"2006","unstructured":"Cheesbrough M. District Laboratory Practice in Tropical Countries Part 2, Second edition. Cambridge University Press, New York, NY; 2006."},{"key":"ref15","unstructured":"Epsilometer test (E test). principle, procedure, results, advantages. (2023). Accessed: 05\/02\/2023: https:\/\/microbenotes.com\/epsilometer-test-e-test\/."},{"key":"ref16","doi-asserted-by":"crossref","DOI":"10.1093\/ajcp\/45.4_ts.493","article-title":"Antibiotic susceptibility testing by a standardized single disk method","volume":"45","author":"Bauer AW","year":"1966","unstructured":"Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966, 45:493-6.","journal-title":"Am J Clin Pathol"},{"key":"ref17","unstructured":"Clinical and laboratory standard institute. M100. Performance standards for antimicrobial susceptibility testing. (2022). Accessed. 24\/12\/2022: https:\/\/clsi.org\/about\/press-releases\/clsi-publishes-m100-performance-standards-for-antimicrobial-susceptibility-test...."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq037","article-title":"Editorial: assessing the antimicrobial susceptibility of bacteria obtained from animals","volume":"65","author":"Schwarz S","year":"2010","unstructured":"Schwarz S, Silley P, Simjee S, Woodford N, van Duijkeren E, Johnson AP, Gaastra W. Editorial: assessing the antimicrobial susceptibility of bacteria obtained from animals. J Antimicrob Chemother. 2010, 65:601-4. 10.1093\/jac\/dkq037","journal-title":"J Antimicrob Chemother"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112829","article-title":"\u03b2-lactam antibiotics: an overview from a medicinal chemistry perspective","volume":"208","author":"Lima LM","year":"2020","unstructured":"Lima LM, Silva BN, Barbosa G, Barreiro EJ. \u03b2-lactam antibiotics: an overview from a medicinal chemistry perspective. Eur J Med Chem. 2020, 208:112829. 10.1016\/j.ejmech.2020.112829","journal-title":"Eur J Med Chem"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1089\/mdr.2011.0072","article-title":"Emergence of extended-spectrum \u03b2-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes","volume":"17","author":"Park SH","year":"2011","unstructured":"Park SH, Choi SM, Lee DG, et al.. Emergence of extended-spectrum \u03b2-lactamase-producing escherichia coli as a cause of community-onset bacteremia in South Korea: risk factors and clinical outcomes. Microb Drug Resist. 2011, 17:537-44. 10.1089\/mdr.2011.0072","journal-title":"Microb Drug Resist"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3201\/eid2507.181938","article-title":"Carbapenem and cephalosporin resistance among Enterobacteriaceae in healthcare-associated infections, California, USA","volume":"25","author":"Rizzo K","year":"2019","unstructured":"Rizzo K, Horwich-Scholefield S, Epson E. Carbapenem and cephalosporin resistance among Enterobacteriaceae in healthcare-associated infections, California, USA. Emerg Infect Dis. 2019, 25:1389-93. 10.3201\/eid2507.181938","journal-title":"Emerg Infect Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1476-0711-12-38","article-title":"A multicentre clinical study on the injection of ceftriaxone\/sulbactam compared with cefoperazone\/sulbactam in the treatment of respiratory and urinary tract infections","volume":"12","author":"Xin X","year":"2013","unstructured":"Xin X, Jian L, Xia X, et al.. A multicentre clinical study on the injection of ceftriaxone\/sulbactam compared with cefoperazone\/sulbactam in the treatment of respiratory and urinary tract infections. Ann Clin Microbiol Antimicrob. 2013, 12:38. 10.1186\/1476-0711-12-38","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics8040184","article-title":"The potential role of sulbactam and cephalosporins plus daptomycin against daptomycin-nonsusceptible VISA and H-VISA isolates: an in vitro study","volume":"8","author":"Lai CC","year":"2019","unstructured":"Lai CC, Chen CC, Lu YC, et al.. The potential role of sulbactam and cephalosporins plus daptomycin against daptomycin-nonsusceptible VISA and H-VISA isolates: an in vitro study. Antibiotics (Basel). 2019, 8:3-7. 10.3390\/antibiotics8040184","journal-title":"Antibiotics (Basel)"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04808-14","article-title":"Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii","volume":"59","author":"Penwell WF","year":"2015","unstructured":"Penwell WF, Shapiro AB, Giacobbe RA, et al.. Molecular mechanisms of sulbactam antibacterial activity and resistance determinants in Acinetobacter baumannii. Antimicrob Agents Chemother. 2015, 59:1680-9. 10.1128\/AAC.04808-14","journal-title":"Antimicrob Agents Chemother"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1016\/S0924-8579(96)80003-3","article-title":"The influence of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime","volume":"6","author":"Bauernfeind A","year":"1996","unstructured":"Bauernfeind A, Grimm H, Klietmann W, Opferkuch W, Werner H. The influence of sulbactam on the in vitro activity of mezlocillin, piperacillin and cefotaxime. Int J Antimicrob Agents. 1996, 6:S15-26.","journal-title":"Int J Antimicrob Agents"},{"key":"ref26","article-title":"MICs and MBCs of cefotaxime, desacetylcefotaxime and ceftriaxone against four principal bacteria causing meningitis (Article in Japanese)","volume":"37","author":"Deguchi K","year":"1984","unstructured":"Deguchi K, Fukuyama S, Nishimura Y, et al.. MICs and MBCs of cefotaxime, desacetylcefotaxime and ceftriaxone against four principal bacteria causing meningitis (Article in Japanese). Jpn J Antibiot. 1984, 37:1701-13.","journal-title":"Jpn J Antibiot"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.9.16.2751","article-title":"Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections","volume":"9","author":"Pareek A","year":"2008","unstructured":"Pareek A, Kulkarni M, Daga S, Deshpande A, Chandurkar N. Comparative evaluation of efficacy and safety of cefotaxime-sulbactam with amoxicillin-clavulanic acid in children with lower respiratory tract infections. Expert Opin Pharmacother. 2008, 9:2751-7. 10.1517\/14656566.9.16.2751","journal-title":"Expert Opin Pharmacother"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2014\/9742.5090","article-title":"Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study","volume":"8","author":"Kaur K","year":"2014","unstructured":"Kaur K, Gupta A, Sharma A, Walia G, Singh B, Kaur K. Evaluation of efficacy and tolerability of cefotaxime and sulbactam versus cefepime and tazobactam in patients of urinary tract infection-a prospective comparative study. J Clin Diagn Res. 2014, 8:HC05-8. 10.7860\/JCDR\/2014\/9742.5090","journal-title":"J Clin Diagn Res"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5455\/njppp.2019.9.1236526122018","article-title":"Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract infections in hospitalized patients: safety and efficacy analysis","volume":"9","author":"Makwana SP","year":"2019","unstructured":"Makwana SP, Solanki MN, Dikshit RK. Cefoperazone + sulbactam versus cefotaxime + sulbactam combination therapy for the treatment of complicated urinary tract infections in hospitalized patients: safety and efficacy analysis. Natl J Physiol Pharm Pharmacol. 2019, 9:187. 10.5455\/njppp.2019.9.1236526122018","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02244-18","article-title":"Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens","volume":"63","author":"Burdet C","year":"2019","unstructured":"Burdet C, Grall N, Linard M, et al.. Ceftriaxone and cefotaxime have similar effects on the intestinal microbiota in human volunteers treated by standard-dose regimens. Antimicrob Agents Chemother. 2019, 63:1-5. 10.1128\/AAC.02244-18","journal-title":"Antimicrob Agents Chemother"},{"key":"ref31","article-title":"Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy","volume":"21","author":"Guggenbichler JP","year":"1986","unstructured":"Guggenbichler JP, Allerberger FJ, Dierich M. Influence of cephalosporines III generation with varying biliary excretion on fecal flora and emergence of resistant bacteria during and after cessation of therapy. Padiatr Padol. 1986, 21:335-42.","journal-title":"Padiatr Padol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198507000-00006","article-title":"Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children","volume":"4","author":"Barson WJ","year":"1985","unstructured":"Barson WJ, Miller MA, Brady MT, Powell DA. Prospective comparative trial of ceftriaxone vs. conventional therapy for treatment of bacterial meningitis in children. Pediatr Infect Dis. 1985, 4:362-8. 10.1097\/00006454-198507000-00006","journal-title":"Pediatr Infect Dis"},{"key":"ref33","article-title":"Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia","volume":"77","author":"Baumgartner JD","year":"1984","unstructured":"Baumgartner JD, Glauser MP. Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia. Am J Med. 1984, 77:54-8.","journal-title":"Am J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199001183220301","article-title":"A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children","volume":"322","author":"Schaad UB","year":"1990","unstructured":"Schaad UB, Suter S, Gianella-Borradori A, et al.. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med. 1990, 322:141-7. 10.1056\/NEJM199001183220301","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.4174\/jkss.2011.81.6.423","article-title":"Gallbladder pseudolithiasis caused by ceftriaxone in young adult","volume":"81","author":"Choi YY","year":"2011","unstructured":"Choi YY, Jung YH, Choi SM, Lee CS, Kim D, Hur KY. Gallbladder pseudolithiasis caused by ceftriaxone in young adult. J Korean Surg Soc. 2011, 81:423-6. 10.4174\/jkss.2011.81.6.423","journal-title":"J Korean Surg Soc"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/132452","article-title":"Acute cholecystitis caused by ceftriaxone stones in an adult","volume":"2009","author":"Becker CD","year":"2009","unstructured":"Becker CD, Fischer RA. Acute cholecystitis caused by ceftriaxone stones in an adult. Case Rep Med. 2009, 2009:132452. 10.1155\/2009\/132452","journal-title":"Case Rep Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa312","article-title":"Switching from ceftriaxone to cefotaxime significantly contributes to reducing the burden of Clostridioides difficile infections","volume":"7","author":"Wendt S","year":"2020","unstructured":"Wendt S, Ranft D, Rodloff AC, Lippmann N, L\u00fcbbert C. Switching from ceftriaxone to cefotaxime significantly contributes to reducing the burden of Clostridioides difficile infections. Open Forum Infect Dis. 2020, 7:ofaa312. 10.1093\/ofid\/ofaa312","journal-title":"Open Forum Infect Dis"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt403","article-title":"Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime","volume":"69","author":"Grohs P","year":"2014","unstructured":"Grohs P, Kern\u00e9is S, Sabatier B, et al.. Fighting the spread of AmpC-hyperproducing Enterobacteriaceae: beneficial effect of replacing ceftriaxone with cefotaxime. J Antimicrob Chemother. 2014, 69:786-9. 10.1093\/jac\/dkt403","journal-title":"J Antimicrob Chemother"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12052","article-title":"A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia","volume":"11","author":"Arnold DM","year":"2013","unstructured":"Arnold DM, Kukaswadia S, Nazi I, et al.. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopenia. J Thromb Haemost. 2013, 11:169-76. 10.1111\/jth.12052","journal-title":"J Thromb Haemost"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-317950","article-title":"Safety of ceftriaxone in paediatrics: a systematic review","volume":"105","author":"Zeng L","year":"2020","unstructured":"Zeng L, Wang C, Jiang M, et al.. Safety of ceftriaxone in paediatrics: a systematic review. Arch Dis Child. 2020, 105:981-5. 10.1136\/archdischild-2019-317950","journal-title":"Arch Dis Child"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/131726-an-in-vitro-susceptibility-study-of-cefotaxime-sulbactam-on-clinical-bacterial-isolates-from-various-regions-in-india-a-comparison-with-ceftriaxone-sulbactam","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:19Z","timestamp":1707508519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/131726-an-in-vitro-susceptibility-study-of-cefotaxime-sulbactam-on-clinical-bacterial-isolates-from-various-regions-in-india-a-comparison-with-ceftriaxone-sulbactam"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,13]]},"references-count":40,"URL":"https:\/\/doi.org\/10.7759\/cureus.36078","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3,13]]}}}